This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients. (A7881013)

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: December 12, 2008
Last updated: October 6, 2011
Last verified: October 2011
To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive Lung Diseases Lung Diseases, Obstructive Drug: PF-00610355 Drug: PF - 00610355 Drug: PF- 00610355 Drug: Placebo Drug: Salmeterol Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b, Parallel Group, Placebo And Active Comparator Controlled Study To Investigate The Safety, Toleration And Efficacy Of 6-Week Once Daily Administration Of Inhaled PF-00610355 Dry Powder In Patients With Moderate Chronic Obstructive Pulmonary Disease.

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Change from baseline in trough FEV1 [ Time Frame: 6 week ]

Secondary Outcome Measures:
  • Maximal and mean changes from baseline in heart rate, QTc and plasma potassium [ Time Frame: each visit ]
  • Change from baseline in peak FEV1 [ Time Frame: 0-6 hours /6 weeks ]
  • Change from baseline in trough and peak FEV6, FVC and IC [ Time Frame: 6 weeks ]
  • Change from baseline in trough FEV1, FEV6, forced vital capacity (FVC) and inspiratory capacity (IC) [ Time Frame: 2 and 4 weeks ]
  • Change from baseline in Respiratory Questionnaire Self-Administered Standardised (CRQ-SAS) [ Time Frame: 2,4,6 weeks ]
  • Change from baseline of COPD symptoms and rescue bronchodilator use (per daily diary). [ Time Frame: weekly ]

Enrollment: 405
Study Start Date: March 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PF-00610355 Drug: PF-00610355
oral, inhaled, dry powder, 600ug, OD
Experimental: PF- 00610355 Drug: PF - 00610355
oral, inhaled, dry powder, 300ug, OD
Experimental: PF - 00610355 Drug: PF- 00610355
oral, inhaled, dry powder, 100ug, OD
Placebo Comparator: Placebo Drug: Placebo
oral, inhaled, dry powder, placebo, OD
Active Comparator: Salmeterol Drug: Salmeterol
salmeterol, 50ug, BID


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Post-bronchodilator FEV1/FVC ratio <0.7 and a post-bronchodilator FEV1 of 50-80%.
  • Diagnosis of moderate COPD for a minimum of 6 months.
  • Stable disease for at least 1 month prior to screening

Exclusion Criteria:

  • More than 2 exacerbations of COPD requiring treatment with oral steroids in the preceding year or hospitalisation for the treatment of COPD within 3 months of screening or more than twice during the preceding year.
  • History of a lower respiratory tract infection or significant disease instability during the month preceding screening or during the time between screening and randomisation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00808288

  Show 75 Study Locations
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT00808288     History of Changes
Other Study ID Numbers: A7881013
Study First Received: December 12, 2008
Last Updated: October 6, 2011

Keywords provided by Pfizer:
COPD Respiratory Long acting beta agonist

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Salmeterol Xinafoate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on September 18, 2017